558 results on '"Tremblay, Douglas"'
Search Results
2. Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy
3. Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement
4. Ven the dose matters: Venetoclax dosing in the frontline treatment of AML
5. New Treatments for Myelofibrosis
6. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment
7. Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights
8. Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis
9. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation
10. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions
11. Novel treatments for myelofibrosis: beyond JAK inhibitors
12. Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide
13. Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients
14. Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database
15. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment
16. Addressing symptom burden in myeloproliferative neoplasms
17. Contemporary and future strategies in polycythemia vera
18. Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells
19. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future
20. Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies.
21. How to customize common data models for rare diseases: an OMOP-based implementation and lessons learned.
22. The effect of novel therapies in high-molecular-risk multiple myeloma.
23. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database
24. Safety, Efficacy, and Long-Term Outcomes of Anticoagulation in Cirrhotic Portal Vein Thrombosis
25. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
26. The Impact of Socioeconomic Status on the Clinical Outcomes of COVID-19; a Retrospective Cohort Study
27. Characteristics, anticoagulation, and outcomes of portal vein thrombosis after intra-abdominal surgery
28. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden
29. Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012 to 2022.
30. Oral Decitabine/Cedazuridine is an Effective Ambulatory Therapy for Patients with Myelofibrosis Refractory to Jak2 Inhibitor Therapy
31. How to customize Common Data Models for rare diseases: an OMOP-based implementation and lessons learned
32. Cytoreduction for ET and PV: who, what, when, and how?
33. Decreased patency of transjugular intrahepatic portosystemic shunts performed for splanchnic vein thrombosis in patients with myeloproliferative neoplasms
34. Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse‐free survival in acute myeloid leukemia.
35. Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation
36. Modern management of splenomegaly in patients with myelofibrosis
37. Novel Therapies in Polycythemia Vera
38. The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes
39. Treatment of Patients in Third Relapse and Beyond Including Double-Refractory Disease
40. Contributors
41. Posttransplant Lymphoproliferative Disorders and Immunodeficiency
42. Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression.
43. Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management.
44. Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012 to 2022
45. Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia
46. POSTER: AML-178 A Multi-Institutional Analysis of Outcomes in Acute Myeloid Leukemia Patients With Central Nervous System Involvement
47. AML-178 A Multi-institutional Analysis of Outcomes in Acute Myeloid Leukemia Patients With Central Nervous System Involvement
48. Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement
49. PB2231: AN OVERLOOKED MIMIC? AUTOIMMUNE MYELOFIBROSIS - A SCOPING REVIEW OF THE LITERATURE
50. Decreased patency of transjugular intrahepatic portosystemic shunts performed for splanchnic vein thrombosis in patients with myeloproliferative neoplasms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.